Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 19/20 | 1.00 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.76 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.74 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.74 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613265 | 0.90 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL18613288 | 0.89 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL20485739 | 0.87 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL4619240 | 0.87 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL18613279 | 0.87 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL18613691 | 0.86 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL30521681 | 0.86 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL17110829 | 0.86 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL29358327 | 0.85 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 | |
| SCHEMBL16026073 | 0.85 | FYN (1.00) | FYNTGFBR1BMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2024-02-08 | — | — | US | claimed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | claimed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | claimed |
| EP-3347462-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | Lau, Warren C. (US) | 2018-07-18 | — | — | EP | claimed |
| WO-2017044623-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | LAU WARREN C (US) | 2017-03-16 | — | — | WO | claimed |
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2024-02-08 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885TGFBR1 3710/4885BMPR1A 3927/4885 |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885TGFBR1 3710/4885BMPR1A 3927/4885 |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885TGFBR1 3710/4885BMPR1A 3927/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885TGFBR1 3710/4885BMPR1A 3927/4885 |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885TGFBR1 3710/4885BMPR1A 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.